Trasylol
Trasylol is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass surgery who are at an increased risk for blood loss and transfusion. Trasylol was manufactured by Bayer Phamaceuticals and was approved by the FDA in 1993. On February 8, 2006, the FDA issued an advisory warning to doctors of the potential for renal toxicity and on November 5, 2007, the FDA and Bayer agreed to temporary marketing suspension of Trasylol. We are investigating potential Trasylol claims involving death after undergoing a coronary artery bypass procedure or kidney failure requiring dialysis or transplant.
Links with more information on Trasylol:
If you or a loved one would like to discuss your legal rights, please call our law offices or, Click here to request a free legal consultation: |
